

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Feige, et al.

Serial No.: Not Yet Assigned

Group Art Unit No.: 1642

Filed: August 18, 2003

Examiner: S. Huff

For: MODIFIED PEPTIDES AS THERAPEUTIC AGENTS

Docket No.: A-527E

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form for consideration by the Examiner.

In accordance with 37 CFR 1.98(d), copies of the patents, publications or other information listed in this information disclosure statement are not required to be provided and are not enclosed because they were previously cited by or submitted to the Office in prior application Serial No. 09/563,286, filed May 3, 2000. The present application is a continuation of this prior application which is relied upon for an earlier filing date under 35 USC 120.

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,



Timothy J. Geur  
Attorney/Agent for Applicants  
Registration No.: 33,111  
Phone: (805) 447-2688  
Date: August 18, 2003

**EXPRESS MAIL CERTIFICATE**

\*Express Mail\* mail labeling number: EV 351339175 US

Date of Deposit: August 18, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Lynne Buchsbaum  
Printed Name

  
Signature

Please send all future correspondence to:

US Patent Operations/ [TJG]  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

Modified Form PTO-1449  <b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docke	Serial No.
	A-527E	Not Yet Assigned
	Applicant Feige et al	
Filing Date	Group	
	August 13, 2003	

### U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	AA	5,223,409	06/29/93	Ladner et al.			
	AB	5,338,665	08/16/94	Schatz et al.			
	AC	5,480,981	01/02/96	Goodwin et al.			
	AD	5,498,530	03/12/96	Schatz et al.			
	AE	5,608,035	03/04/97	Yanofsky et al.			
	AF	5,733,731	03/31/98	Schatz et al.			
	AG	5,739,277	04/14/98	Presta et al.			
	AH	5,767,234	06/16/98	Yanofsky et al.			
	AI	5,773,569	06/30/98	Wrighton et al.			
	AJ	5,786,331	07/28/98	Barrett et al.			
	AK	5,869,451	02/09/99	Dower et al.			
	AL	5,869,452	02/09/99	Ng et al.			
	AM	5,877,151	03/03/99	Pereira Heloise Anne			
	AN	5,880,096	03/09/99	Barrett et al.			
	AO	5,922,545	07/13/99	Mattheakis et al.			
	AP	5,932,546	08/03/99	Barrett et al.			
	AQ	5,432,018	07/11/99	Dower et al.			
	AR	5,945,5075,432,018	08/31/99	Mietzner et al.			

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449  <b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket	Serial No.
	A-527E	Not Yet Assigned
	Applicant	
	Feige et al	
Filing Date	August 13, 2003	Group

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	CLASS	TRANSLATION	
							YES	NO
	BA	WO 94/07921	04/14/94	PCT				
	BB	WO 95/09917	04/13/95	PCT				
	BC	WO 95/14714	06/01/95	PCT				
	BD	WO 96/05309	02/22/96	PCT				
	BE	WO 96/11214	04/18/96	PCT				
	BF	WO 96/11953	04/25/96	PCT				
	BB	WO 96/17942	06/13/96	PCT				
	BG	WO 96/18412	06/20/96	PCT				
	BH	WO 96/30057	10/03/96	PCT				
	BI	WO 96/40772	12/19/96	PCT				
	BJ	WO 96/40987	12/19/96	PCT				
	BK	WO 97/00270	01/03/97	PCT				
	BN	WO 97/08203	03/06/97	PCT				
	BO	WO 97/08553	03/06/97	PCT				
	BP	WO 97/23614	07/03/97	PCT				
	BQ	WO 96/23899	08/08/96	PCT				
	BR	WO 97/28828	08/14/97	PCT				
	BS	WO 97/31019	08/28/97	PCT				
	BT	WO 97/34631	09/25/97	PCT				
	BU	WO 97/35969	10/02/97	PCT				
	BV	WO 97/40070	10/30/97	PCT				
	BW	WO 97/41220	04/29/97	PCT				
	BX	WO 97/44453	11/27/97	PCT				
	BY	WO 98/09985	03/12/98	PCT				
	BZ	WO 98/10795	03/19/98	PCT				

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449  <b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket	Serial No.
	A-527E	Not Yet Assigned
	Applicant	
	Feige et al	
Filing Date	Group	
	August 13, 2003	

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	CLASS	TRANSITION	YES	NO
	B1	WO 98/15833	04/16/98	PCT					
	B2	WO 98/24477	06/11/98	PCT					
	B3	WO 98/28427	07/02/98	PCT					
	B4	WO 98/31820	07/23/98	PCT					
	B5	WO 98/33812	08/06/98	PCT					
	B6	WO 98/46257	10/22/98	PCT					
	B7	WO 98/53842	12/03/98	PCT					
	B8	WO 98/55620	12/10/98	PCT					
	B9	WO 99/05302	02/04/99	PCT					
	B10	WO 99/14244	03/25/99	PCT					
	B11	WO 99/17789	04/15/99	PCT					
	B12	WO 99/18243	04/15/99	PCT					
	B13	WO 99/18781	04/22/99	PCT					
	B14	WO 99/24462	05/20/99	PCT					
	B15	WO 00/24782	05/04/00	PCT					
	B16	WO 99/42592	08/26/99	PCT					
	B17	WO 99/47151	09/23/99	PCT					
	B18	WO 99/50282	10/07/99	PCT					
	B19	WO 99/51254	10/14/99	PCT					
	B20	WO 99/60013	11/25/99	PCT					
	B21	WO 99/61476	12/02/99	PCT					
	B22	WO 99/62539	1/20/99	PCT					
	B23	WO 00/00632	01/06/00	PCT					
	B24	WO 00/01402	01/13/00	PCT					
	B25	WO 00/04048	01/27/00	PCT					

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[illegible]

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449  <b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket	Serial No.
	A-527E	Not Yet Assigned
	Applicant	
	Feige et al	
	Filing Date	Group
	August 13, 2003	

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Adey et al. (1996), 'Identification of calmodulin-binding peptide consensus sequences from a phage-displayed random peptide library', <i>Gene</i> 169:133-134.
CB	Adey et al. (1997), 'Isolation of peptides from phage-displayed random peptide libraries that interact with the talin-binding domain of vinculin', <i>Biochem. J.</i> 324:523-528.
CC	Ahern et al. (1990), 'Special Report: The Peptide-Oligonucleotide Partnership', <i>The Scientist</i> 4 (19):24-25.
CD	Akeson et al. (1996), 'AF12198, a Novel Low Molecular Weight Antagonist, Selectively Binds the Human Type I Interleukin (IL)-1 Receptor and Blocks in vivo Responses to IL-1', <i>J. Biol. Chem.</i> 271:30517-30523.
CE	Ball et al. (1997), 'Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21 <sup>WAF1</sup> ', <i>Current Biology</i> 7:71-80.
CF	Barna et al. (1994), "Combination therapy with a synthetic peptide of C-reactive protein and interleukin 2: augmented survival and eradication of pulmonary metastases," <i>Cancer Immunol. Immunother.</i> 38:38-42.
CG	Bhatnagar et al. (1996), 'Structure-Activity Relationships of Novel Hematopoietic Peptides', <i>J. Med. Chem.</i> 39:3814-3819.
CH	Böttger et al. (1997), 'Molecular Characterization of the hdm2-p53 Interaction', <i>J. Mol. Biol.</i> 269:744-756.
CI	Böttger et al. (1996), 'Identification of novel mdm2 binding peptides by phage display', <i>Oncogene</i> 13:2141-2147.
CJ	Brocks et al. (1997), "A TNF Receptor Antagonistic scFv, Which is Not Secreted in Mammalian Cells, is Expressed as a Soluble Mono- and Bivalent scFv Derivative in Insect Cells," <i>Immunotechnology</i> 3(3): 173-184.
CK	Burstein et al. (1988), 'Thymic Humoral Factor γ2: Purification and Amino Acid Sequence of an Immunoregulatory Peptide from Calf Thymus', <i>Biochemistry</i> 27:4066-4071.
CL	Capon et al. (1989), 'Designing CD4 Immunoconjugates for AIDS Therapy', <i>Nature</i> 337:525-531.
CM	Chan and Kim (1998), "HIV Entry and Its Inhibition" <i>Cell</i> 93:681-684.
CN	Chirinos-Rojas et al. (1998), 'A Peptidomimetic Antagonist of TNF-α-Mediated Cytotoxicity Identified from a Phage-Displayed Random Peptide Library', <i>Journal of Immunology</i> 161:5621-5626.
CO	Cooper et al. (1987), 'Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients', <i>PNAS</i> 84:8628-8632.
CP	Cortese et al. (1996), 'Selection of biologically active peptides by phage display of random peptide libraries', <i>Current Opinion in Biotechnology</i> 7:616-621.
CQ	Couet et al. (1997), 'Identification of Peptide and Protein Ligands for the Caveolin-scaffolding Domain', <i>The Journal of Biological Chemistry</i> 272 (10):6525-6533.
CR	Couet et al. (1997), 'Interaction of a Receptor Tyrosine Kinase, EGF-R, with Caveolins', <i>The Journal of Biological Chemistry</i> Vol 272 (48):30429-30438.
CS	Cuthbertson et al. (1997), 'Design of Low Molecular Weight Hematopoietic Agents from the Structure-Activity Relationship of a Dimeric Pentapeptide', <i>J. Med. Chem</i> 40:2876-2882.
CT	Cwirla et al. (1997), 'Peptide Agonist of the Thrombopoietin Receptor', <i>Science</i> 276:1696-1699.
CU	Dedman et al. (1993), 'Selection of Targeted Biological Modifiers from a Bacteriophage Library of Random Peptides', <i>The Journal of Biological Chemistry</i> 268 (31):23025-23030.
CV	Devlin et al. (1990), 'Random Peptide Libraries: A Source of Specific Protein Binding Molecules', <i>Science</i> 249:404-406.
CW	Duncan et al. (1988), 'Localization of the binding site for the human high-affinity Fc receptor on IgG', <i>Nature</i> 332:563-564.

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Modified Form PTO-1449  <b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket	A-527E	Serial No.	Not Yet Assigned
	Applicant	Feige et al		
	Filing Date	August 13, 2003	Group	

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	CX	Dyson et al. (1995), 'Selection of peptide inhibitors of interactions involved in complex protein assemblies: Association of the core and surface antigens of hepatitis B virus', <i>Proc. Natl. Acad. Sci. USA</i> 92:2194-2198.
	CY	Fahraeus et al. (1996), 'Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A', <i>Current Biology</i> 6:84-91.
	CZ	Fairbrother et al. (1998), 'Novel Peptides Selected to Bind Vascular Endothelial Growth Factor Target the Receptor-Binding Site', <i>Biochemistry</i> 37:17754-17764.
	C1	Fisher et al. (1996), 'Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein', <i>N. Eng. J. Med.</i> 334(26):1697-1702.
	C2	Francis, Gillian E. (1992), 'Protein modification and fusion proteins', <i>Focus on Growth</i> 3:4-11.
	C3	Fukumoto et al. (1998), 'Peptide mimics of the CTLA4-binding domain stimulate T-cell proliferation', <i>Nature Biotechnology</i> , 16:267-270.
	C4	Gan et al. (1988), 'Echistatin', <i>JBC</i> 263:19827-19832.
	C5	Ghetie et al. (1997), 'Increasing the serum persistence of an IgG fragment by random mutagenesis', <i>Nature Biotechnology</i> 15:637-640.
	C6	Gibbs et al. (1994), 'Pharmaceutical Research in Molecular Oncology', <i>Cell</i> 79:193-198.
	C7	Gibbs et al. (1994), 'Farnesyltransferase Inhibitors: Ras Research Yields a Potential Cancer Therapeutic', <i>Cell</i> 77:175-178.
	C8	Goodson et al. (1994), 'High-affinity urokinase receptor antagonists identified with bacteriophage peptide display', <i>Proc. Natl. Acad. Sci. USA</i> 91:7129-7133.
	C9	Graf and Kastin (1986), "Delta-Sleep-Inducing Peptide (DSIP): An Update" <i>Peptides</i> 7:1165-1187.
	C10	Harvill et al. (1995), 'An IgG3-IL2 fusion protein activates complement, binds FcγRI, generates LAK activity and shows enhanced binding to the high affinity IL-2R', <i>Immunotech.</i> 1:95-105.
	C11	Harwig et al. (1994), "Neutrophil Defensins: Purification, Characterization, and Antimicrobial Testing" <i>Methods Enzymology</i> 236:160-172.
	C12	Herz et al. (1997), 'Molecular Approaches to Receptors as Targets for Drug Discovery', <i>J. of Receptor &amp; Signal Transduction Research</i> 17(5):671-776.
	C13	Hong et al. (1995), 'Protein ligands of the human adenovirus type 2 outer capsid identified by biopanning of a phage-displayed peptide library on separate domains of wild-type and mutant penton capsomers', <i>The EMBO Journal</i> 14:4714-4727.
	C14	Hughes, David (1998), 'Therapeutic antibodies make a comeback', <i>Drug Discovery Today</i> 3(10):439-442.
	C15	Inagaki-Ohara et al. (1996), 'Effects of a Nonapeptide Thymic Hormone on Intestinal Intraepithelial Lymphocytes in Mice Following Administration of 5-Fluorouracil', <i>Cellular Immunology</i> 17:30-40.
	C16	Inglot, Anna D. (1997), 'Classification of Cytokines According to the Receptor Code', <i>Archivum Immunologies et Therapine Experimentalis</i> 45:353-357.
	C17	Jefferies, D. (1998), 'Selection of Novel Ligands from Phage Display Libraries: An Alternative Approach to Drug and Vaccine Discovery?', <i>Parasitology Today</i> 14(5):202-206.
	C18	Jefferis et al. (1995), 'Recognition sites on human IgG for Fcγ receptors: the role of glycosylation', <i>Immunology Letters</i> 44:111-117.
	C19	Jefferis et al. (1990), 'Molecular Definition of Interaction Sites on Human IgG for Fc Receptors (huFcγ R)', <i>Molecular Immunology</i> 27(12):1237-1240.

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Modified Form PTO-1449  <b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docke	A-527F.	Serial No.	Not Yet Assigned	
	Applica nt	Feige et al			
	Filing Date	August 13, 2003		Group	

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C20	Johnson et al. (1998), "Identification of a 13 Amino Acid Peptide Mimetic of Erythropoietin and Description of Amino Acids Critical for the Mimetic Activity of EMP1," <i>Biochemistry</i> 37(11): 3699-3710.
C21	Jones et al. (1998), 'Stromal Expression of Jagged 1 Promotes Colony Formation by Fetal Hematopoietic Progenitor Cells', <i>Blood</i> 92(5):1505-1511.
C22	Junghans, R.P. (1997), 'Finally! The Brambell Receptor (FcRB)', <i>Immunologic Research</i> 16(1):29-57.
C23	Kay et al. (1998), 'From peptides to drugs via phage display', <i>DDT</i> 3(8): 370-378.
C24	King et al. (1991), 'Modulation of Bone Marrow Stromal Cell Production of Colony Stimulating Activity by the Synthetic Peptide', <i>Exp. Hematol.</i> 19:481.
C25	King et al. (1995), 'Hematoregulatory Peptide, SK&F Induced Stromal Cell Production of KC Enhances CFU-GM Growth and Effector Cell Function', <i>Blood</i> 86(1):309a
C26	Kitamura et al. (1993), 'Adrenomedullin: A Novel Hypotensive Peptide Isolated from Human Pheochromocytoma', <i>BBRC</i> 192:553-560.
C27	Kluczyk et al. (1997), 'Immunomodulatory Activity of Oligopeptides Related to Interleukin 1 Receptor Antagonist Sequence', <i>Archivum Immunologic et Therapiae Experimentalis</i> 45:427-433.
C28	Koivunen et al. (1999), 'Tumor targeting with a selective gelatinase inhibitor', <i>Nature Biotech.</i> 17:768-774.
C29	Kreeger, Karen Young (1998), 'Immunological Applications Top List of Peptide-Synthesis Services', <i>The Scientist</i> 10(13):19-20.
C30	Laerum et al. (1988), 'The Dimer of Hemoregulatory Peptide (HP5B) Stimulates Mouse and Human Myelopoiesis in vitro', <i>Exp. Hemat.</i> 16:274-280.
C31	Linse et al. (1997), 'A Region of Vitamin K-dependent Protein S That Binds to C4b Binding Protein (C4BP) Identified Using Bacteriophage Peptide Display Libraries', <i>The Journal of Biological Chemistry</i> 272(23):14658-14665.
C32	Linsley et al. (1991), 'CTLA-4 is a Second Receptor for the B Cell Activation Antigen B7', <i>J. Exp. Med.</i> 174:561-569.
C33	Livnah et al. (1996), 'Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8 Å', <i>Science</i> 273:464-471.
C34	Loetscher et al. (1993), "Efficacy of a Chimeric TNFR-IgG Fusion Protein to Inhibit TNF Activity in Animal Models of Septic Shock," <i>International Congress Series</i> 2: 455-462.
C35	Lowman, H.B. (1997), 'Bacteriophage display and discovery of peptide leads for drug development', <i>Annu. Rev. Biophys. Biomol. Struct.</i> 26:401-24.
C36	Lundergan et al. (1999), "Angiotensin-II increases cytoplasmic calcium, cell number and total DNA for human periodontal ligamental cells in vitro" <i>J. Periodontal Res.</i> 34(4):223-228.
C37	Martens et al. (1995), 'Peptides which bind to E-selectin and block neutrophil adhesion', <i>The Journal of Biological Chemistry</i> 270(36):21129-21136.
C38	McGregor, Duncan (1996), 'Selection of proteins and peptides from libraries displayed on filamentous bacteriophage', <i>Molecular Biotechnology</i> 6:155-162.
C39	Moodie et al. (1994), 'The 3Rs of Life: Ras, Raf and Growth Regulation', <i>TIG</i> 10(2):44-48.
C40	Moonga et al. (1998), "Effects of Peptide Fragments of Protein Kinase C on Isolated Rat Osteoclasts" <i>Experimental Physiology</i> 83:717-725.
C41	Morikis et al. (1998), 'Solution structure of Compstatin, a potent complement inhibitor', <i>Protein Science</i> 7:619-627.

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>Modified Form PTO-1449</b>  <b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket <b>A-527E</b>	Serial No. <b>Not Yet Assigned</b>
	Applica nt <b>Feige et al</b>	
	Filing Date <b>August 13, 2003</b>	Group

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C42	Naranda et al. (June, 1999), "Activation of erythropoietin receptor in the absence of hormone by a peptide that binds to a domain different from the hormone binding site," <i>Proc. Natl. Acad. Sci. USA</i> 96:7569-7574.
C43	Nishi et al. (1996), 'Tight-binding inhibitory sequences against pp60 <sup>c-src</sup> identified using a random 15-amino-acid peptide library', <i>FEBS</i> 399:237-240.
C44	Park et al. (2000), "Rationally designed anti-HER2/neu peptide mimetic disables P185 <sup>HER2/neu</sup> tyrosine kinases in vitro and in vivo" <i>Nature Biotechnology</i> 18:194-198.
C45	Pasquaimi et al. (1996), 'Organ targeting in vivo using phage display peptide libraries', <i>Nature</i> 380:364-366.
C46	Paukovits et al. (1984), 'Structural Investigations on a Peptide Regulating Hemopoiesis in vitro and in vivo', <i>Hoppe-Seylers Z Physiol. Chem</i> 364:303-311.
C47	Pawson et al. (1993), 'SH2 and SH3 Domains', <i>Current Biology</i> 3(7):434-442.
C48	Pierce et al. (1995), 'Identification of cyclized calmodulin antagonists from a phage display random peptide library', <i>Molecular Diversity</i> 1:259-265.
C49	Piette et al. (1997), "Mdm2: keeping p53 under control", <i>Oncogene</i> 15:1001-1010.
C50	Powis, Garth (1991), 'Signalling targets for anticancer drug development', <i>TIPS</i> 12:188-194.
C51	Rickles et al. (1994), 'Identification of Src, Fyn, Lyn, PI3K and Abl SH3 domain ligands using phage display libraries', <i>The EMBO Journal</i> 13(23):5598-5604.
C52	Rodriguez-Viciana et al. (1994), 'Phosphatidylinositol-3-OH kinase as a direct target of Ras', <i>Nature</i> 370:527-532.
C53	Sahu et al. (1996), 'Inhibition of Human Complement by a C3-Binding Peptide Isolated from a Phage-Displayed Random Peptide Library', <i>The Journal of Immunology</i> 157:884-891.
C54	Sarmay et al. (1992), 'Mapping and Comparison of the Interaction Sites on the Fc Region of IgG Responsible for Triggering Antibody Dependent Cellular Cytotoxicity (ADCC) Through Different Types of Human Fcγ Receptor', <i>Molecular Immunology</i> 29(5):633-639.
C55	Scott et al. (1990), 'Searching for Peptide Ligands with an Epitope Library', <i>Science</i> 249:386-390.
C56	Siemion et al. (1991), 'The Evidence on the Possible Interleukin-1α Tuftsin Competition', <i>Archivum Immunologiae et Therapiae Experimentalis</i> 39:605-611.
C57	Sparks et al. (1996), 'Distinct ligand preferences of Src homology 3 domains from Src, Yes, Abl, Cortactin, p53bp2, PLCγ, Crk, and Grb2', <i>Proc. Natl. Acad. Sci. USA</i> 93:1540-1544.
C58	Sparks et al. (1994), 'Identification and Characterization of Src SH3 Ligands from Phage-displayed Random Peptide Libraries', <i>The Journal of Biological Chemistry</i> 269(39):23853-23856.
C59	Stauffer et al. (1997), 'Inhibition of Lyn Function in Mast Cell Activation by SH3 Domain Binding Peptides', <i>Biochemistry</i> 36:9388-9394.
C60	Suzuki and Yoshino (1992), "The Relationship Between Amino Acid Sequences of Sperm-Activating Peptides and the Taxonomy of Echinoids" <i>Comp. Biochem. Physiol.</i> 102B:679-690.
C61	Takasaki et al. (1997), 'Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNFα binding to its receptor', <i>Nature Biotechnology</i> 15:1266-1270.
C62	Van Zee et al. (1996), 'Protection Against Lethal Escherichia coli Bacteremia in Baboons (Papio anubis) by Pretreatment with a 55-kDa TNF Receptor (CD120a)-Ig Fusion Protein, Ro 45-2081', <i>J. Immunol.</i> 156:2221-2230.

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

[illegible]

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.